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•

RESULTS

OBJECTIVE
To characterize the use of vancomycin medication therapy at a non-profit
community hospital (Parkview Regional Medical Center) in preparation for a
potential change to AUC:MIC dosing and monitoring.

• 3386 subjects screened → 1973 subject pool → 300 subject random
sample → 264 subject final random sample

METHODS

Median age (year, IQR)
Median weight (kg, IQR)
Body Mass Index (BMI) Classification (n, %)
Underweight (BMI < 20 kg/m2)
Healthy weight (BMI 20 – 24.9 kg/m2)
Overweight (BMI 25 – 29.9 kg/m2)
Class I obesity (BMI 30 – 34.9 kg/m2)
Class II obesity (BMI 35 – 39.9 kg/m2)
Class III obesity (BMI ≥ 40 kg/m2)
Male sex (n, %)
Use of prior IV antibiotics within 90 days (n, %)
Prior MRSA culture collected within 5 years (n, %)
Positive MRSA nasal swab during admission (n, %)
Number of orders originating from the Emergency Department (n, %)
Pharmacy to dose consult (n,%)
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Figure 5: Concomitant Nephrotoxic Medications Among Patients with AKI During
this Admission (n = 25)
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*Each patient who experienced AKI were exposed to at least one concomitant nephrotoxic medication during admission

DISCUSSION & CONCLUSIONS

2.66%
1.52%
10%

15%

Median length of stay (days, IQR)
Median number of vancomycin doses per patient (IQR)
Median duration of vancomycin therapy (days, IQR)
Mean number of vancomycin levels drawn per patient (SD)
Percentage of patients receiving a loading dose (%)
Surgical intervention involved (n, %)
Median time to de-escalation (days, IQR)

Figure 2: Initial Dosing of Intervals of Vancomycin
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6 (3.5 – 11)
4 (2 – 6)
2 (1.5 – 3.5)
1.49 ± 0.82
61
33 (13)
2 (1.5 – 3.5)

Figure 3: Result of De-escalation
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Table 2: Vancomycin Patient Outcomes

*If the patient was admitted > 1 time during the study period, only the first encounter was used for data collection

1.47%
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2.94%

156 (59)

4.18%
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4.56%

URINARY TRACT INFECTION

6.86%

0%

5.70%

OTHER

8.82%

METRONIDAZOLE

20.53%

BACTEREMIA

11.27%

CARBAPENEM

27.38%

CNS INFECTION

11.76%

SFX/TMP

SKIN & SOFT TISSUE INFECTION

Located in
the operating room
at time of ordering

• Data was extracted from the institution's electronic medical record system and
manually validated
• Using a random number generator in Microsoft Excel, a subset of 300 patients
were chosen to analyze. Upon further review, an additional 36 patients met
exclusion criteria and were removed from the analysis.
• Patient demographics, laboratory values, concomitant medications and culture
data were gathered.
• Patients were categorized based on whether their vancomycin was:
• Discontinued, changed to alternate oral therapy, changed to alternate IV
therapy, completed, or continued outpatient
• Incidence of acute kidney injury (AKI) was evaluated with respect to
concomitant nephrotoxic medications and increases in serum creatinine
• AKI was defined as a rise of serum creatinine by 0.3 mg/dL or more within 48
hours of a vancomycin dose being given
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Figure 1: Percent of Vancomycin Orders by Indication (n = 264)

CARDIAC INDICATION

• Retrospective analysis at PRMC between January 1, 2021 through May 31, 2022
• Inclusion criteria: > 18 years of age, ≥ 2 doses of vancomycin received
• Exclusion criteria:
Orders for any form of dialysis

CEPHALOSPORIN

Table 1: Baseline Characteristics (n = 264)

• Vancomycin is a bactericidal glycopeptide antibiotic that inhibits cell wall
synthesis. The spectrum of activity is limited to only gram-stain positive
bacteria; however, it is effective against methicillin resistant Staphylococcus
aureus (MRSA) for which it is the mainstay of treatment.1
• Currently, pharmacodynamic monitoring of vancomycin efficacy and safety is
by drug trough evaluation when at steady state (typically prior to the fourth
dose). For patients who have sporadic renal function (i.e., new onset acute
kidney injury, rapidly declining chronic kidney disease, or undergoing
hemodialysis), a random drug level may be drawn for closer monitoring.1
• Infectious Disease Society of America (IDSA) guidelines cite some evidence
that an AUC:MIC dosing strategy may allow clinicians to evaluate
vancomycin dosing before steady state (as soon as the second dose), promoting
quicker times to therapeutic range and decreased incidence of vancomycin
induced nephrotoxicity.2
• Monitoring via AUC:MIC is especially beneficial in those with critical illness.
For all, the acceptable AUC:MIC therapeutic range is 400 – 600 mg-hr/L,
whereas a ratio > 650 mg-hr/L has been associated with an increased incidence
of acute kidney injury.2

Transfer from
outlying facility

Figure 4: Subsequent Antibiotic Orders After Vancomycin De-escalation (n = 178)

• Most excluded due to transfer from other facility (43%) or dialysis orders (39%)
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• Parkview Health’s vancomycin dosing protocol of a 25 mg/kg loading dose for serious
infections and a 15 mg/kg (actual body weight) maintenance dose resulted in an AKI
incidence of 9.5%, and a median time to de-escalation of 2 days within the study period.
• Most commonly, vancomycin was started for indications of fever & illness of unknown
etiology, followed by skin and soft tissue infections, and pneumonia. According to IDSA
pneumonia guidelines, empiric coverage of MRSA is not warranted unless specific
criteria are met (IV antibiotics within 90 days or prior positive culture of MRSA). These
criteria were not met for many patients empirically being treated for pneumonia.
• A small percentage of patients received MRSA nasal swabs (including nasal cultures and
nasal PCR tests) although a larger percentage of patients had an indication of
pneumonia and/or skin and soft tissue infections for which the testing has evidence to
support. There may be potential for more frequent utilization of a MRSA nasal swab.
• Among those who possibly experienced AKI due to vancomycin, each were exposed to at
least one prespecified concomitant nephrotoxic drug class during their admission.
• The cost benefit debate of purchasing Bayesian software against manually validating
lower-cost alternatives for AUC:MIC vancomycin dosing will require further discussion
primarily based around the relatively short time to de-escalation and low incidence of
positive MRSA cultures.
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